Nebivolol Accord (Nebivolol Hydrochloride)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility. It also stimulates endothelial nitric‑oxide release, causing vasodilation of peripheral vessels. The combined actions lower cardiac output and peripheral resistance, resulting in reduced arterial pressure.

The appropriate dose of Nebivolol Accord is determined by the prescribing clinician based on the patient’s blood pressure, age, renal function, and overall health. Dosage adjustments are made individually; patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To request Nebivolol Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nebivolol is a third‑generation beta‑blocker that offers both β1‑selectivity and nitric‑oxide‑mediated vasodilation, which may provide better tolerability compared with older non‑selective beta‑blockers. Unlike some calcium‑channel blockers, it does not cause significant peripheral edema, making it a useful alternative for patients who experience that side effect.

Nebivolol Accord should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Nebivolol Accord is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include marked bradycardia, severe hypotension, heart block, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience fainting, rapid weight gain, swelling, or difficulty breathing.

Nebivolol should be avoided in patients with severe bradycardia, second‑ or third‑degree atrioventricular block, uncompensated heart failure, or a known hypersensitivity to nebivolol or any excipients. Caution is also advised for individuals with asthma, chronic obstructive pulmonary disease, or significant liver impairment.